Alamethicin
(Synonyms: 丙甲菌素) 目录号 : GC11255A membrane active peptide antibiotic
Cas No.:27061-78-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >90.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Alamethicin is an antibiotic peptide.
Plenty of peptide antibiotics have been identified in the past half-century, falling into two classes, non-ribosomally synthesized peptides, such as polymyxins, gramicidins, bacitracins, glycopeptides, and ribosomally synthesized (natural) peptides. The former are usually modified and produced by bacteria, while the latter are produced by all species as a major component of the host defense molecules.
In vitro: Alamethicin was identified as an antibiotic peptide belonging to membrane active peptides of fungal origin with an unusual amphiphilic amino acid, 2-aminoisobutyric acid, which can induce helical peptide structures strongly, leading to the formation of voltage-gated ion channels in the cell membrane bilayers. Alamethicin is also widely used as agent to induce various defense responses and physiological in eukaryotic cells [1]. In addition, alamethicin was quite often used to evaluate voltage gating, ion channel assembly, as well as peptide-membrane interactions [2, 3].
In vivo: Up to now, alamethicin is only for in-vitro usage and there is no animal in-vivo study reported.
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Maischak, H. ,Zimmermann, M.R.,Felle, H.H., et al. Alamethicin-induced electrical long distance signaling in plants. Plant Signal.Behav. 5(8), 988-990 (2010).
[2] Jones, L. R.,Maddock, S.W. and Besch, H.R., Jr. Unmasking effect of alamethicin on the (Na+,K+)-ATPase, β-adrenergic receptor-coupled adenylate cyclase, and cAMP-dependent protein kinase activities of cardiac sarcolemmal vesicles. The Journal of Biological Chemisty 255(20), 9971-9980 (1980).
[3] Pan, J. ,Tristram-Nagle, S. and Nagle, J.F. Alamethicin aggregation in lipid membranes. Journal of Membrane Biology 231(1), 1-36 (2009).
| Cas No. | 27061-78-5 | SDF | |
| 别名 | 丙甲菌素 | ||
| 化学名 | (3S,12R)-1-((S)-1-((6S,12S,15S,21S,30S)-1-((R)-1-(2-acetamido-2-methylpropanoyl)pyrrolidin-2-yl)-15-(3-amino-3-oxopropyl)-30-isobutyl-21-isopropyl-3,3,6,9,9,12,18,18,24,24,33,33-dodecamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaoxo-2,5,8,11,14,17,20,23,26, | ||
| Canonical SMILES | CC(C[C@H](NC(CNC(C(C)(NC([C@@H](NC(C(C)(NC([C@@H](NC([C@@H](NC(C(C)(NC([C@@H](NC(C(C)(NC([C@H]1CCCN1C(C(C)(NC(C)=O)C)=O)=O)C)=O)C)=O)C)=O)C)=O)CCC(N)=O)=O)C)=O)C(C)C)=O)C)=O)=O)C(NC(C)(C(N2CCC[C@H]2C(N[C@H](C(NC(C)(C(NC(C)(C(N[C@@H](C(N[C@@H](C(N[C@H | ||
| 分子式 | C92H150N22O25 | 分子量 | 1964.3 |
| 溶解度 | ≤10mg/ml in methanol;10mg/ml in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5091 mL | 2.5454 mL | 5.0909 mL |
| 5 mM | 0.1018 mL | 0.5091 mL | 1.0182 mL |
| 10 mM | 0.0509 mL | 0.2545 mL | 0.5091 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。